ClinicalTrials.gg
CompletedNCT04003844Updated May 21, 2020

Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease

A Phase 4 interventional study of Immunoglobulin G and Acetylsalicylic acid in Kawasaki Disease, sponsored by Green Cross Corporation. Completed at 7 sites in Korea, Republic of. Open to participants aged 3 Months to 12 Years. Per ClinicalTrials.gov, last updated 2020-05-21.

Sponsored by Green Cross Corporation · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2019, registered May 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
3 Months to 12 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of high-dose human Immunoglobulin G Intravenous (IGIV) 10% in subjects with Kawasaki diseases (KD).

Read the detailed description

This is a multicenter, single-arm, and open-label clinical trial to evaluate the coronary artery lesions (CALs) at 2 and 7 weeks after single dose of IGIV 10% (2 g/kg) administration for at least 12 hours to evaluate the efficacy and safety of IGIV 10%.

02

Conditions studied

  • Kawasaki Disease
03

In context

Mucocutaneous Lymph Node Syndrome

62 studies on the registry are indexed under Mucocutaneous Lymph Node Syndrome; 17 are open to participants now.

This study's enrollment of 45 is close to the median of 45 across 33 interventional studies indexed under Mucocutaneous Lymph Node Syndrome.

Browse Mucocutaneous Lymph Node Syndrome studies →

Lead sponsor

Green Cross Corporation is the lead sponsor of 63 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Infants and children aged 3 months to 7 years inclusive, at the time of signing the , however, patients with complete KD are eligible up to 12 years (applies to 2A)
  2. Subjects with fever 4-10 days meeting one of following criteria (A, B or C)

    A. Subjects with at least 4 of the following principal clinical findings:

    i) Bilateral bulbar conjunctival injection without exudate

    ii) Erythema and cracking of lips, strawberry tongue, and/or erythema of oral and pharyngeal mucosa

    iii) Erythema and edema of the hands and feet in acute phase and/or periungual desquamation in subacute phase

    iv) Cervical lymphadenopathy (≥1.5 cm diameter), usually unilateral

    v) Rash: maculopapular, diffuse erythroderma, or erythema multiforme-like

    B. Subjects with at least 3 of the principal clinical findings and coronary artery abnormalities detected by 2-dimensional echocardiography: Z score of left anterior descending coronary artery or right coronary artery ≥2.5

    C. Subjects without coronary artery abnormalities, but with fever ≥5 days, 2 or 3 of the principal clinical findings , CRP of ≥3.0 mg/dL and meeting 3 or more of the following laboratory findings:

    i) Albumin \<3.0 g/dL

    ii) Anemia for age

    iii) Elevated level

    iv) count of >450,000/mm3 after the 7th day of fever

    v) White blood cell count of >15,000/mm3

    vi) Urine >10 white blood cells/high-power field

  3. Subjects whose subject's parents or legally authorized representative gave voluntary written consent to participate in the clinical trial

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of KD
  2. Subjects with following laboratory findings:

    A. count \<100,000/mm3

    B. WBC count \<3,000 cells/mm3

    C. , hematocrit or red blood cell count more than 30% above the upper limit or 30% below the lower limit of the normal range

  3. Subjects who are currently receiving or who have received any drug or device within 30 days prior to administration of the IP
  4. Subjects who have received TNF alpha antagonist or systemic within 48 hours prior to administration of the IP
  5. Subjects who are considered by the investigator to be an unsuitable candidate for the study due to a severe chronic disease (e.g. cardiovascular disease except controllable hypertension, respiratory disease with respiratory failure, metabolic disease, renal failure, hemoglobinopathy, etc.)
  6. Subjects who have received or immunomodulatory drugs within 3 months prior to administration of the IP
  7. Subjects with immunodeficiency including known positive serology for (HIV)
  8. Subjects with a history of or shock to IVIG formulations
  9. Subjects with underlying liver disease or liver dysfunction with known etiology
  10. Subjects with renal impairment whose creatinine level is more than twice the
  11. Subjects with a history of malignant tumor
  12. Subjects with a history of IgA deficiency
  13. Subjects who are considered by the investigator to be an unsuitable candidate for the study for any reason
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Experimental

    Investigational product (IP)

    Drug: Immunoglobulin G · Drug: Acetylsalicylic acid

Interventions

06

What researchers measure

Primary outcomes

  1. incidence of CALs

    incidence of CALs at 7 weeks after treatment

    Time frame: 7 weeks

Secondary outcomes

  1. incidence of CALs

    incidence of CALs at 2 weeks after treatment

    Time frame: 2 weeks

  2. total duration of fever

    total duration of fever after treatment

    Time frame: baseline

  3. laboratory measurements : markers of inflammation and cardiovascular disease

    measurement of erythrocyte sedimentation rate (ESR)

    Time frame: 7 weeks

  4. laboratory measurements : markers of inflammation and cardiovascular disease

    measurement of C-reactive protein (CRP)

    Time frame: 7 weeks

  5. laboratory measurements : markers of inflammation and cardiovascular disease

    measurement of N-terminal pro B-type natriuretic peptide (NTproBNP) or B-type natriuretic peptide (BNP)

    Time frame: 7 weeks

  6. laboratory measurements : markers of inflammation and cardiovascular disease

    measurement of creatine kinase-myocardial band (CK-MB)

    Time frame: 7 weeks

  7. laboratory measurements : markers of inflammation and cardiovascular disease

    measurement of procalcitonin

    Time frame: 7 weeks

  8. laboratory measurements : markers of inflammation and cardiovascular disease

    measurement of soluble suppression of tumorigenicity 2 (sST2)

    Time frame: 7 weeks

  9. laboratory measurements : markers of inflammation and cardiovascular disease

    measurement of Troponin I

    Time frame: 7 weeks

  10. IGIV resistance

    frequency of IGIV resistance

    Time frame: baseline

  11. adverse events, adverse drug reactions and serious adverse events

    number of adverse events, adverse drug reactions and serious adverse events

    Time frame: 7 weeks

  12. laboratory measurements : hematological parameters

    measurement of white blood cell (WBC)

    Time frame: 7 weeks

  13. laboratory measurements : hematological parameters

    measurement of red blood cell (RBC)

    Time frame: 7 weeks

  14. laboratory measurements : hematological parameters

    measurement of hemoglobin

    Time frame: 7 weeks

  15. laboratory measurements : hematological parameters

    measurement of hematocrit

    Time frame: 7 weeks

  16. laboratory measurements : hematological parameters

    measurement of platelet count

    Time frame: 7 weeks

  17. laboratory measurements : clinical chemistry parameters

    measurement of alanine transaminase (ALT)

    Time frame: 7 weeks

  18. laboratory measurements : clinical chemistry parameters

    measurement of albumin

    Time frame: 7 weeks

  19. laboratory measurements : urinalysis

    measurement of WBC (urine microscopy)

    Time frame: 7 weeks

  20. vital signs: blood pressure

    measurement of systolic and diastolic blood pressure

    Time frame: 7 weeks

  21. vital signs: body temperature

    measurement of body temperature

    Time frame: 7 weeks

  22. physical examination

    visual inspection of general appearance, head, eyes, nose-mouth-throat, lymph nodes, skin, extremities for abnormal findings

    Time frame: 7 weeks

07

Study locations

7 sites
  • Hallym University Sacred Heart Hospital
    Anyang, Korea, Republic of
  • Asan Medical Center
    Seoul, Korea, Republic of
  • Kyung Hee University Hospital at Gangdong
    Seoul, Korea, Republic of
  • Kyung Hee University Medical Center
    Seoul, Korea, Republic of
  • Severance Hospital
    Seoul, Korea, Republic of
  • The Catholic University of Korea Seoul St. Mary's Hospital
    Seoul, Korea, Republic of
  • Wonju Severance Christian Hospital
    Wonju, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Nov 2019, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2019
First posted
Jul 1, 2019
StartActual
Feb 1, 2019
Primary completionActual
Nov 22, 2019
CompletionActual
Nov 22, 2019
Last update
May 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04003844
Responsible party
Sponsor
First posted
Jul 1, 2019
Start date
Feb 1, 2019
Primary completion
Nov 22, 2019
Completion
Nov 22, 2019
Last update
May 21, 2020

Study contacts

Mi Young Han, MD, Ph.D.
principal investigator · Kyunghee University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion